CLP Magazine publishes article written by Translational’s CEO, Don Rule, “Implementing a Pharmacogenomics Program”


To optimize the implementation and potential benefits of a pharmacogenomic testing program, significant consideration should be given to choosing the right pharmacogenomic test menu, educating healthcare providers and patients, and seamlessly integrating pharmacogenomic data and clinical decision support (CDS) systems into existing clinical processes and systems.


Laboratories can also play a vital role in helping clinicians order and interpret genetic tests by supporting the use of genomic decision support tools within the clinical workflow. Such tools take into account the patient’s current medication list, pharmacogenetic profile, and other factors in order to guide clinical decisions about which tests and drugs are most appropriate for the patient.


Among recent advances in this area are pharmacogenomic-based application programming interfaces (APIs) developed using the fast healthcare interoperability resources (FHIR) specification, a new open-source standard for ensuring interoperability and security while exchanging healthcare information. FHIR-based APIs are enabling health systems, laboratories, and software developers to accelerate the development of pharmacogenomic-enhanced applications via plug-and-play access to existing pharmacogenomic knowledge platforms.


read more